A Case of HER2-Positive Advanced Breast Cancer Who Was Able to Start and Continue Chemotherapy Despite Liver Damage Due to Diffuse Liver Metastasis
49-year-old woman, who diagnosed advanced breast cancer with, ER-positive, HER2-positive, T4bN1M1, Stage Ⅳ. At the time of initial diagnosis, liver damage equivalent to Child-Pugh classification C due to diffuse liver metastasis was observed, but trastuzumab/pertuzumab(HP)and paclitaxel(PTX)adjusted according to liver function were administered every 3 weeks, resulting in rapid improvement of liver function, PR of the primary tumor(90% reduction), PR of the liver metastases(70% reduction), and improvement of tumor markers. Currently, chemotherapy has been switched to docetaxel (DTX)due to peripheral neuropathy caused by PTX, and treatment is continuing. In the case of HER2-positive breast cancer, good disease control may be achieved with aggressive treatment and intervention under dose adjustment and careful systemic management, even in the setting of liver injury.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Gan to kagaku ryoho. Cancer & chemotherapy - 50(2023), 13 vom: 02. Dez., Seite 1739-1741 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Fujimoto, Takuya [VerfasserIn] |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Completed 05.02.2024 Date Revised 06.02.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM367925559 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367925559 | ||
| 003 | DE-627 | ||
| 005 | 20240206232147.0 | ||
| 007 | tu | ||
| 008 | 240202s2023 xx ||||| 00| ||jpn c | ||
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM367925559 | ||
| 035 | |a (NLM)38303191 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Fujimoto, Takuya |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Case of HER2-Positive Advanced Breast Cancer Who Was Able to Start and Continue Chemotherapy Despite Liver Damage Due to Diffuse Liver Metastasis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2024 | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a 49-year-old woman, who diagnosed advanced breast cancer with, ER-positive, HER2-positive, T4bN1M1, Stage Ⅳ. At the time of initial diagnosis, liver damage equivalent to Child-Pugh classification C due to diffuse liver metastasis was observed, but trastuzumab/pertuzumab(HP)and paclitaxel(PTX)adjusted according to liver function were administered every 3 weeks, resulting in rapid improvement of liver function, PR of the primary tumor(90% reduction), PR of the liver metastases(70% reduction), and improvement of tumor markers. Currently, chemotherapy has been switched to docetaxel (DTX)due to peripheral neuropathy caused by PTX, and treatment is continuing. In the case of HER2-positive breast cancer, good disease control may be achieved with aggressive treatment and intervention under dose adjustment and careful systemic management, even in the setting of liver injury | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 700 | 1 | |a Maeda, Noriko |e verfasserin |4 aut | |
| 700 | 1 | |a Ioka, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Nagano, Hiroaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gan to kagaku ryoho. Cancer & chemotherapy |d 1993 |g 50(2023), 13 vom: 02. Dez., Seite 1739-1741 |w (DE-627)NLM012601861 |x 0385-0684 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:13 |g day:02 |g month:12 |g pages:1739-1741 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 13 |b 02 |c 12 |h 1739-1741 | ||